DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tigatuzumab
Tigatuzumab
Molecular Imaging of Death Receptor 5 Occupancy and Saturation Kinetics in Vivo by Humanized Monoclonal Antibody CS-1008
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Activating Death Receptor DR5 As a Therapeutic Strategy for Rhabdomyosarcoma
Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
Tanibirumab (CUI C3490677) Add to Cart
Pancreatic Cancer Stem Cells in Patient Pancreatic Xenografts Are Sensitive to Drozitumab, an Agonistic Antibody Against DR5 Jason W.-L
The Two Tontti Tudiul Lui Hi Ha Unit
NSCLC Therapeutics in Asia-Pacific Markets to 2019 Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
(INN) for Biological and Biotechnological Substances
Ep 3321281 A1
Focus on Approved and In-Clinical-Trial Monoclonal Antibodies
INN Working Document 05.179 Update 2011
Novel Agents for Advanced Pancreatic Cancer
Stembook 2018.Pdf
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
(12) Patent Application Publication (10) Pub. No.: US 2016/0184445 A1 Perroth Et Al
Top View
(INN) for Biological and Biotechnological Substances
Ep 2739649 B1
A61K9/51 (2006.01) — with International Search Report (Art
First-Line Treatment of Patients with Advanced Or Metastatic Squamous Non-Small Cell Lung Cancer: Systematic Review and Network Meta-Analysis
N° 18380 A61k 31/5377 (2018.01) A61p 35/02 (2018.01)
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Wo 2010/095940 A2
Mai Muita in Acut Ca Uti on Muunni
Assessment of the Evolution of Cancer Treatment Therapies
Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
Pharmaabkommen A1 E
Biotechnology Presented by America’S Biopharmaceutical Research Companies
Pharmaceutical Products and Chemical Intermediates, Fourth Review: Advice Concerning the Addition of Certain Products to the Pharmaceutical Appendix to the HTS
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
1587.Full-Text.Pdf
Com(2010)0397
University of Groningen Targeted Therapy, Molecular Imaging And
Principles of Antibody-Mediated TNF Receptor Activation
(12) United States Patent (10) Patent No.: US 9,345,770 B2 Storkus Et Al
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
International Journal of Current Advanced Research
Curriculum Vitae and Bibliography Paul Haluska, Jr., MD, Phd
Association of Adaptive Early Phase Study Design and Late Phase Study Results in Oncology Donna Elise Levy Walden University
Protein-Polymer-Drug Conjugates Protein-Polymer-Wirkstoffkonjugate Conjugués De Médicament-Protéine-Polymère
Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
(INN) for Biological and Biotechnological Substances
Medicines & Vaccines in Development for Cancer
Ep 3088005 A1
Icis) and Multikinase Inhibitors (Mkis) (N= 49
Assessment of the Evolution of Cancer Treatment Therapies
Oncology Drugs in the Pipeline
Pre-Activation of the P53 Pathway Through Nutlin-3A Sensitises Sarcomas to Drozitumab Therapy
Assessment of the Evolution of Cancer Treatment Therapies
(12) Patent Application Publication (10) Pub. No.: US 2014/0322132 A1 Vitalis Et Al
Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
On the TRAIL to Successful Cancer Therapy? Predicting and Counteracting Resistance Against TRAIL-Based Therapeutics
Human BMPR1B Amino Acid Sequence
Safety and Efficacy of Tigatuzumab Plus Sorafenib As First-Line Therapy
Targeting TM4SF5 with Anti‑TM4SF5 Monoclonal Antibody Suppresses the Growth and Motility of Human Pancreatic Cancer Cells